Prognostic value of NOB1 expression levels in various cancers: a systematic review and meta-analysis.
Yi ZhangZheng LiXi ChenYing HuangBingwen ZouYong XuPublished in: Biomarkers in medicine (2024)
Aim: This study evaluates the prognostic significance of NOB1 expression levels in various cancers. Patients & methods: Studies examining NOB1 expression in cancer, encompassing data from 1694 patients across 14 studies, were analyzed for overall survival (OS) and progression-free survival (PFS) using hazard ratios (HRs) and 95% CIs, and for clinicopathological parameters using relative risks (RRs). Results: High NOB1 expression correlated with shorter OS (HR: 2.12, 95% CI: 1.82-2.48) and PFS (HR: 2.23, 95% CI: 1.62-3.07) and was associated with adverse tumor characteristics such as stage and metastasis. Conclusion: Elevated NOB1 expression in various tumors signifies a poor prognosis, serving as a predictive marker for malignancy outcomes. PROSPERO Register Number: CRD42023394051.
Keyphrases
- poor prognosis
- long non coding rna
- end stage renal disease
- free survival
- chronic kidney disease
- newly diagnosed
- ejection fraction
- binding protein
- prognostic factors
- squamous cell carcinoma
- metabolic syndrome
- emergency department
- type diabetes
- patient reported outcomes
- big data
- artificial intelligence
- climate change
- lymph node metastasis
- papillary thyroid
- squamous cell